32 related articles for article (PubMed ID: 15732332)
1. Low-dose diethylstilbestrol for the treatment of advanced prostate cancer.
Clemons J; Glodé LM; Gao D; Flaig TW
Urol Oncol; 2013 Feb; 31(2):198-204. PubMed ID: 21795073
[TBL] [Abstract][Full Text] [Related]
2. Effects of etoposide combined with cisplatin on prognosis of patients with castration-resistant prostate cancer who failed castration treatment.
Liu F; Zhang H; Sun Z; Meng X; Ma Z; Wang Z
Am J Transl Res; 2022; 14(3):1705-1713. PubMed ID: 35422924
[TBL] [Abstract][Full Text] [Related]
3. An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer.
Salzberg M; Rochlitz C; Morant R; Thalmann G; Pedrazzini A; Roggero E; Schönenberger A; Knuth A; Borner M
Onkologie; 2007 Jul; 30(7):355-60. PubMed ID: 17596743
[TBL] [Abstract][Full Text] [Related]
4. Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).
Kattan JG; Farhat FS; Chahine GY; Nasr FL; Moukadem WT; Younes FC; Yazbeck NJ; Ghosn MG;
Invest New Drugs; 2008 Feb; 26(1):75-9. PubMed ID: 17846704
[TBL] [Abstract][Full Text] [Related]
5. Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer: a retrospective comparative study with weekly docetaxel alone.
Shimazui T; Kawai K; Miyanaga N; Kojima T; Sekido N; Hinotsu S; Oikawa T; Joraku A; Akaza H
Jpn J Clin Oncol; 2007 Aug; 37(8):603-8. PubMed ID: 17673473
[TBL] [Abstract][Full Text] [Related]
6. Weekly administration of docetaxel in patients with hormone-refractory prostate cancer: a pilot study on Japanese patients.
Kojima T; Shimazui T; Onozawa M; Tsukamoto S; Hinotsu S; Miyanaga N; Hattori K; Kawai K; Akaza H
Jpn J Clin Oncol; 2004 Mar; 34(3):137-41. PubMed ID: 15078909
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer.
Safarinejad MR
Urol Oncol; 2005; 23(2):93-101. PubMed ID: 15869993
[TBL] [Abstract][Full Text] [Related]
8. [Combination chemotherapy with docetaxel and cisplatin in patients with hormone-refractory prostate cancer].
Fujinami K; Miura T; Takizawa A; Osada Y
Hinyokika Kiyo; 2005 Jan; 51(1):5-8. PubMed ID: 15732332
[TBL] [Abstract][Full Text] [Related]
9. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
Van Poppel H
Can J Urol; 2005 Feb; 12 Suppl 1():81-5. PubMed ID: 15780173
[TBL] [Abstract][Full Text] [Related]
10. The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.
Berry WR
Urology; 2005 Jun; 65(6 Suppl):2-7. PubMed ID: 15939076
[TBL] [Abstract][Full Text] [Related]
11. Second-line chemotherapy for hormone-refractory prostate cancer: has the time come?
Rosenberg JE; Small EJ
Clin Prostate Cancer; 2004 Sep; 3(2):122-4. PubMed ID: 15479496
[TBL] [Abstract][Full Text] [Related]
12. The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer.
McKeage MJ
Expert Opin Investig Drugs; 2008 Jan; 17(1):23-9. PubMed ID: 18095916
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
